Published in Open Access J Urol on May 03, 2011
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 19.74
Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 14.35
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Androgen receptor in prostate cancer. Endocr Rev (2004) 7.92
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res (2009) 6.83
Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med (1996) 6.11
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 5.72
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol (1999) 4.12
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer (2009) 4.12
Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene (2009) 3.90
Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol (2009) 3.51
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol (2000) 3.48
Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res (2000) 2.89
Immunological aspects of malignant disease. Lancet (1967) 2.66
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell (2005) 2.37
New therapies for castration-resistant prostate cancer. N Engl J Med (2010) 2.37
Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis (2004) 2.33
Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res (1994) 2.10
The spontaneous regression of cancer. A review of cases from 1900 to 1987. Acta Oncol (1990) 2.08
Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA (2000) 1.90
Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci (2007) 1.89
Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res (2000) 1.81
Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol (1997) 1.80
Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol (2002) 1.77
Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer (1994) 1.76
Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol (2004) 1.71
A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother (2010) 1.70
Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res (2010) 1.54
Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate (2004) 1.50
Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer (2008) 1.48
Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol (2001) 1.46
A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer (2004) 1.45
Regulation of androgen receptor levels: implications for prostate cancer progression and therapy. J Cell Biochem (2005) 1.41
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol (2003) 1.35
Autoimmune prostatitis: evidence of T cell reactivity with normal prostatic proteins. Urology (1997) 1.26
CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine (2004) 1.25
Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer. Prostate (2001) 1.17
DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother (2010) 1.12
Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. Hum Immunol (2010) 1.08
Whole-cell vaccines: A failure or a success waiting to happen? Curr Opin Mol Ther (2010) 1.07
Current status of immunological therapies for prostate cancer. Curr Opin Urol (2010) 1.06
Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate (1999) 1.05
Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease. Expert Opin Biol Ther (2008) 1.02
Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res (2009) 1.01
The functioning antigens: beyond just as the immunological targets. Cancer Sci (2009) 1.01
Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients. Clin Cancer Res (2010) 1.00
HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother (2010) 0.99
Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J Clin Oncol (2007) 0.96
Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer. Prostate (2007) 0.95
Humoral immune responses to testis antigens in sera from patients with prostate cancer. Cancer Immun (2006) 0.95
A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Clin Cancer Res (2009) 0.94
A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol Rev (2008) 0.92
Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide. Cancer Immunol Immunother (2005) 0.92
Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma. J Immunother (2005) 0.90
Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients. Oncol Rep (2004) 0.87
Autoimmune T cell responses to seminal plasma in chronic pelvic pain syndrome (CPPS). Clin Exp Immunol (2002) 0.85
Target antigens for prostate cancer immunotherapy. Cancer Metastasis Rev (1999) 0.85
GM-CSF-secreting vaccines for solid tumors. Curr Opin Investig Drugs (2009) 0.84
Identification of T helper epitopes from prostatic acid phosphatase. Cancer Res (2001) 0.80
Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice. Cancer Immunol Immunother (2006) 0.77
Provenge approval means sensitive coverage decisions. Manag Care (2010) 0.76
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res (2009) 2.32
Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. Cancer Res (2011) 1.66
The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. Cancer Immunol Immunother (2012) 1.50
Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine (2005) 1.23
Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells. Cancer Immunol Immunother (2006) 1.20
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol (2007) 1.14
DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother (2010) 1.12
Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunol Immunother (2011) 1.11
Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol (2012) 1.09
Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor. Prostate (2007) 1.09
Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. Hum Immunol (2010) 1.08
The SSX family of cancer-testis antigens as target proteins for tumor therapy. Clin Dev Immunol (2010) 1.06
An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans. J Clin Invest (2009) 1.01
Identification of autoantibodies elicited in a patient with prostate cancer presenting as dermatomyositis. Int J Urol (2006) 1.01
HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother (2010) 0.99
Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells. J Immunother (2011) 0.97
Prioritization of cancer antigens: keeping the target in sight. Expert Rev Vaccines (2009) 0.96
Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer. Prostate (2007) 0.95
Current controversies in the management of biochemical failure in prostate cancer. Clin Adv Hematol Oncol (2012) 0.95
Endothelin receptor antagonists in cancer therapy. Cancer Invest (2007) 0.95
Humoral immune responses to testis antigens in sera from patients with prostate cancer. Cancer Immun (2006) 0.95
Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clin Cancer Res (2009) 0.94
Identification of antigen-specific IgG in sera from patients with chronic prostatitis. J Clin Immunol (2004) 0.93
DNA vaccines for the treatment of prostate cancer. Expert Rev Vaccines (2010) 0.91
Immunotherapy for prostate cancer - recent progress in clinical trials. Clin Adv Hematol Oncol (2007) 0.91
IgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacy. J Biomed Biotechnol (2010) 0.90
Newer therapies in advanced prostate cancer. Clin Prostate Cancer (2004) 0.90
Antigen-specific IgG elicited in subjects with prostate cancer treated with flt3 ligand. J Immunother (2005) 0.90
Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels - a pharmacodynamic study. Invest New Drugs (2006) 0.89
MAD-CT-2 identified as a novel melanoma cancer-testis antigen using phage immunoblot analysis. J Immunother (2007) 0.88
GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther (2007) 0.88
Antibody responses to prostate-associated antigens in patients with prostatitis and prostate cancer. Prostate (2011) 0.86
CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells. Cancer Immunol Immunother (2011) 0.84
Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence. Expert Rev Vaccines (2012) 0.83
Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response. Oncoimmunology (2012) 0.83
A negative selection methodology using a microfluidic platform for the isolation and enumeration of circulating tumor cells. Methods (2013) 0.83
Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. Prostate (2011) 0.81
A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors. Clin Cancer Res (2008) 0.81
Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens. Immunobiology (2003) 0.81
A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy. Clin Genitourin Cancer (2013) 0.80
T cells localized to the androgen-deprived prostate are TH1 and TH17 biased. Prostate (2011) 0.80
Monitoring regulatory immune responses in tumor immunotherapy clinical trials. Front Oncol (2013) 0.79
Vaccination using peptides spanning the SYT-SSX tumor-specific translocation. Expert Rev Vaccines (2012) 0.79
Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes. Prostate (2011) 0.79
A phase I study of a DNA vaccine targeting prostatic Acid phosphatase in patients with stage D0 prostate cancer. Clin Genitourin Cancer (2005) 0.78
Prostate carcinoma in transgenic Lewis rats - a tumor model for evaluation of immunological treatments. Chin Clin Oncol (2013) 0.76
Identification of autoantibodies in a patient with testicular cancer and concurrent inflammatory bowel disease. J Clin Oncol (2010) 0.75
Methods for constructing and evaluating antitumor DNA vaccines. Methods Mol Biol (2009) 0.75